BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38418189)

  • 1. [Clinical characteristics and prognostic factors of breast cancer patients with tumor deposits in the ipsilateral axillary region].
    Xiao JJ; Huang ML; Yan CJ; Ling R; Wei HL
    Zhonghua Zhong Liu Za Zhi; 2024 Feb; 46(2):146-154. PubMed ID: 38418189
    [No Abstract]   [Full Text] [Related]  

  • 2. [Prognostic value and initial exploratory research on TNM staging method of tumor deposits in stage III colon cancer].
    Qin Q; Yang L; Zhou AP; Wang JW; Zhong DS
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Dec; 22(12):1152-1158. PubMed ID: 31874531
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinicopathological characteristics and prognostic factors of breast cancer with estrogen- and progesterone-receptor negative and HER-2 overexpression].
    Fan Y; Guan Y; Zhao WH; Li Q; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):917-20. PubMed ID: 19173993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
    Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of locally advanced breast cancer patients with ≥ 10 positive axillary lymph nodes.
    Koca E; Kuzan TY; Dizdar O; Babacan T; Sahin I; Ararat E; Altundag K
    Med Oncol; 2013; 30(3):615. PubMed ID: 23729267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Analysis of risk factors of axillary lymph node metastasis and prognosis in T1 breast cancer: a large-scale retrospective study based on the SEER database].
    Wang WY; Meng XZ; Li N; Zeng HM; Liu JX; Feng KX; Wang PL; Wang X
    Zhonghua Yi Xue Za Zhi; 2021 Jul; 101(27):2152-2158. PubMed ID: 34275251
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical significance of extranodal extension in sentinel lymph node positive breast cancer.
    Yang X; Ma X; Yang W; Shui R
    Sci Rep; 2020 Sep; 10(1):14684. PubMed ID: 32895434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response.
    Resende U; Cabello C; Ramalho SOB; Zeferino LC
    BMC Cancer; 2019 Jun; 19(1):601. PubMed ID: 31208353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of extranodal extension in axillary lymph node-positive breast cancer.
    Ma X; Yang X; Yang W; Shui R
    Sci Rep; 2021 May; 11(1):9534. PubMed ID: 33953240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients.
    Kassem L; Deygas M; Fattet L; Lopez J; Goulvent T; Lavergne E; Chabaud S; Carrabin N; Chopin N; Bachelot T; Gillet G; Treilleux I; Rimokh R
    BMC Cancer; 2015 Jun; 15():453. PubMed ID: 26040677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The importance of extracapsular extension of axillary lymph node metastases in breast cancer.
    Ilknur GB; Hilmi A; Tülay C; Oguz C; Selma S; Serdar S; Uğur Y; Pinar B; Omer H; Münir K;
    Tumori; 2004; 90(1):107-11. PubMed ID: 15143982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prognosis and risk factors of 1 791 patients with breast cancer treated with breast-conserving surgery based on real-world data].
    Chen SY; Tang Y; Song YW; Wang SL; Jin J; Liu YP; Wang WH; Fang H; Ren H; Sun GY; Wang JY; Jing H; Zhang JH; Liu XF; Yu ZH; Li YX
    Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):619-625. PubMed ID: 30139034
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].
    Li Q; Xu BH; Zhang P; Li Q; Yuan P; Wang JY; Luo Y; Ma F; Fan Y; Li Q
    Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):207-11. PubMed ID: 23880002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of adjuvant trastuzumab on long-term survival of T1N0M0 stage human epidermal growth factor receptor 2 positive breast cancer: a real-world study].
    Sun TH; Lu ZN; Song HT; Sun G
    Zhonghua Zhong Liu Za Zhi; 2023 Jan; 45(1):101-107. PubMed ID: 36709127
    [No Abstract]   [Full Text] [Related]  

  • 15. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.
    Caudle AS; Yu TK; Tucker SL; Bedrosian I; Litton JK; Gonzalez-Angulo AM; Hoffman K; Meric-Bernstam F; Hunt KK; Buchholz TA; Mittendorf EA
    Breast Cancer Res; 2012 May; 14(3):R83. PubMed ID: 22621334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy of adjuvant endocrine therapy in breast cancer patients with a positive-to-negative switch of hormone receptor status after neoadjuvant chemotherapy].
    Xia G; Zhu J; Yuan J; Cao B; Tang J; Chen Y
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2016 May; 45(6):614-619. PubMed ID: 28247605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy.
    Swisher SK; Vila J; Tucker SL; Bedrosian I; Shaitelman SF; Litton JK; Smith BD; Caudle AS; Kuerer HM; Mittendorf EA
    Ann Surg Oncol; 2016 Mar; 23(3):749-56. PubMed ID: 26511263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
    Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
    World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated expression of MTDH predicts better prognosis of locally advanced HER-2 positive breast cancer patients receiving neoadjuvant chemotherapy plus trastuzumab.
    Wang X; Cai L; Ye F; Li M; Ma L; Geng C; Song Z; Liu Y
    Medicine (Baltimore); 2019 Sep; 98(36):e16937. PubMed ID: 31490377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical features and prognosis analysis of different breast cancer molecular subtypes].
    Yang Q; Chen J; Li HJ; Yu M; Tian CX; Lü Q
    Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):42-6. PubMed ID: 21575463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.